Please login to the form below

Not currently logged in
Email:
Password:

Nimbus Therapeutics

This page shows the latest Nimbus Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Gilead chalks up trial success for new NASH drug

Gilead chalks up trial success for new NASH drug

Along with selonsertib, Gilead is also developing an FXR agonist called GS-9674 in phase I trials and acquired a wholly-owned subsidiary of Nimbus Therapeutics for $1.2bn earlier this ... Allergan has been building a pipeline of candidates through a

Latest news

  • Torrid times at Gilead lead to calls for a major M&A deal Torrid times at Gilead lead to calls for a major M&A deal

    The company has a history of making successful bolt-on acquisitions - adding its HIV blockbusters with the purchase of Triangle Therapeutics in 2003 and hepatitis portfolio by buying Pharmasset in 2011 - ... Smaller deals - including a $1.2bn deal for

  • FDA panel backs Intercept's rare liver disease drug FDA panel backs Intercept's rare liver disease drug

    As a NASH therapy Ocaliva could face competition from Gilead Sciences' simtuzumab (in phase II), an earlier stage acetyl-CoA carboxylase (ACC) inhibitor candidate just acquired from Nimbus Therapeutics, as well

  • Gilead boosts liver disease pipeline with $1.2bn acquisition Gilead boosts liver disease pipeline with $1.2bn acquisition

    Gilead Sciences boosted its pipeline of treatments for liver disease by buying a subsidiary of Nimbus Therapeutics in a deal that could be worth up to $1.2bn to the US ... In addition to the upfront payment of $400m, Nimbus Therapeutics also stands to

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest appointments

  • ARC names chairman and member of the board ARC names chairman and member of the board

    Iwicki is executive chairman of the board of directors of Kala Pharmaceuticals and sits on the boards of Nimbus Therapeutics and Taris Biomedical. ... He was president and CEO of Civitas Therapeutics until late 2014 and prior to this, held the same

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics